Cargando…

India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further

Detalles Bibliográficos
Autores principales:	Udwadia, Zarir F, Furin, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614616/ https://www.ncbi.nlm.nih.gov/pubmed/34747748 http://dx.doi.org/10.4103/lungindia.lungindia_425_21

Ejemplares similares

Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? – Authors' reply
por: Udwadia, Zarir, et al.
Publicado: (2021)

Optimal management of drug-resistant tuberculosis: Can India lead the way?
por: Masini, Tiziana, et al.
Publicado: (2023)

Quality of drug-resistant tuberculosis care: Gaps and solutions
por: Udwadia, Zarir, et al.
Publicado: (2019)

Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant “XDR” tuberculosis patients on bedaquiline during COVID-19 pandemic
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Why “covering all” in the DOTS program is not necessarily “all being covered” by the DOTS program
por: Pinto, Lancelot Mark, et al.
Publicado: (2010)

Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis
por: Tack, Ilse, et al.
Publicado: (2020)

Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug
por: Jain, Nirmal Kumar
Publicado: (2022)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2022)

COVID-19 care in India: the course to self-reliance
por: Balsari, Satchit, et al.
Publicado: (2020)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2023)

Speed up multi-pathogen surveillance
por: Li, Chengjun, et al.
Publicado: (2023)

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
por: Udwadia, Zarir F, et al.
Publicado: (2016)

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
por: Rosu, Laura, et al.
Publicado: (2020)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

The All-India Medical Licentiates' Association
por: Chakraborty, Sarat Chandra
Publicado: (1930)

Tuberculosis Management by Private Practitioners in Mumbai, India: Has Anything Changed in Two Decades?
por: Udwadia, Zarir F., et al.
Publicado: (2010)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India
por: Balsari, Satchit, et al.
Publicado: (2021)

Procrastination
Publicado: (1889)

Further Challenges
por: Jirles, B
Publicado: (2000)

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic
por: Udwadia, Zarir F., et al.
Publicado: (2019)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Bedtime procrastination: introducing a new area of procrastination
por: Kroese, Floor M., et al.
Publicado: (2014)

Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015)

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
por: Snobre, J., et al.
Publicado: (2023)

The Mediator Role of Routines on the Relationship between General Procrastination, Academic Procrastination and Perceived Importance of Sleep and Bedtime Procrastination
por: Magalhães, Paula, et al.
Publicado: (2021)

Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2021)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB
por: Lewis, Joseph M., et al.
Publicado: (2016)

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China
por: Agnarson, Abela Mpobela, et al.
Publicado: (2020)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality
por: Danchin, Nicolas, et al.
Publicado: (2019)

Further Education of Medical Licentiates
por: Biswas, S. S.
Publicado: (1949)

Further Research on Epidemic Dropsy
por: Lal, R. B.
Publicado: (1937)

Further Success with Potassii Nitras
por: Cock, L. W.
Publicado: (1890)

Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis
por: Patankar, Sayalee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o4u27p15gvbbqa0cjdjit1411u